Showing 1 - 7 of 7
<Emphasis Type="Bold">Background: There have been several explorations of factors influencing the reimbursement decisions of the National Institute for Health and Clinical Excellence (NICE) but not of other UK-based health technology assessment (HTA) organizations. <Emphasis Type="Bold">Objective: This study aimed to explore the factors...</emphasis></emphasis>
Persistent link: https://www.econbiz.de/10011001744
Cost estimates for the drug of interest, its comparator and concomitant drugs are an important component of pharmacoeconomic evaluations. However, whilst in general considerable efforts are made by analysts to ensure valid and accurate parameter inputs, the methods for estimating drug costs are...
Persistent link: https://www.econbiz.de/10010848939
Accurate resource-use measurement is challenging within an economic evaluation, but is a fundamental requirement for estimating efficiency. Considerable research effort has been concentrated on the appropriate measurement of outcomes and the policy implications of economic evaluation, while...
Persistent link: https://www.econbiz.de/10011000684
Persistent link: https://www.econbiz.de/10010634530
Non-compliance with prescribed regimens poses a significant problem in clinical therapeutics - patients who do not take their medications according to the labelling instructions are at higher risk of treatment failure, and this may have adverse effects on health outcome and healthcare costs....
Persistent link: https://www.econbiz.de/10005449157
Persistent link: https://www.econbiz.de/10005449171
Persistent link: https://www.econbiz.de/10005404997